HSPA5 and acute myeloid leukemia: Jetani et al developed a CAR-T cell targeting Siglec-6, which preclinical model studies showed were anti-leukemic-responsive and could induce complete tumor remission in xenograft AML models.96 Hebbar et al reported a GRP78-CAR-T cell with significant anti-AML activity in vivo without toxicity to hematopoietic progenitor cells.97 A phase I study of CLL-1 CAR-T cells showed complete response (CR)/CR with incomplete hematologic recovery (CRi) rate of 70% and an OS rate of 60%.